Stockscreener 앱 받기
4.48
2.75%
0.12
Pluri Inc 주식(PLUR)의 최신 뉴스
Pluri Inc. Announces Appointment of Alejandro Weinstein to Board of Directors -January 23, 2025 at 07:15 am EST - Marketscreener.com
Pluri Strengthens Leadership Amid Strategic Board Appointment - TipRanks
Pluri Inc. granted extension to regain Nasdaq compliance - MSN
Pluri gets $6.5M investment from Alejandro Weinstein, enters cacao market - Yahoo Finance
BeZero closes $32m round: The Week in AgriFoodTech - AgFunderNews
Pluri Secures $6.5 Million Investment and Acquires Majority Stake in Cell-Based Cacao Producer Kokomodovegconomist - vegconomist - the vegan business magazine
Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition - The Manila Times
Pluri Secures $6.5M Premium Investment, Acquires Majority Stake in Cultivated Cacao Pioneer - StockTitan
Comparing Adverum Biotechnologies (NASDAQ:ADVM) & Pluri (NASDAQ:PLUR) - Defense World
Anavex Life Sciences (NASDAQ:AVXL) vs. Pluri (NASDAQ:PLUR) Critical Comparison - Defense World
BCLI: Plans Coming Together for Phase 3b Trial of NurOwn® in ALS… - MSN
Pluristyx Announces Immediate Availability of GMP-Compliant PSXi013 iPSC Line for Advanced Therapy Development - Business Wire
Head to Head Review: Pluri (NASDAQ:PLUR) & Gilead Sciences (NASDAQ:GILD) - Defense World
Pluristem stock touches 52-week low at $4.11 amid market challenges - Investing.com India
Pluristem stock touches 52-week low at $4.11 amid market challenges By Investing.com - Investing.com South Africa
BrainStorm secures FDA protocol for ALS trial By Investing.com - Investing.com Canada
Financial Contrast: Evaxion Biotech A/S (NASDAQ:EVAX) & Pluri (NASDAQ:PLUR) - Defense World
BrainStorm Issues 2024 Letter to Shareholders - The Malaysian Reserve
BrainStorm secures FDA protocol for ALS trial - Investing.com India
BrainStorm Issues 2024 Letter to Shareholders – Company Announcement - Financial Times
Pluri (NASDAQ:PLUR) Trading Down 2.8% – Here’s Why - Defense World
Pluri Congratulates Mesoblast on FDA Approval of Cell Therapy for Graft-Versus-Host Disease - Content Media Solution
Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease - The Manila Times
Pluri (PLUR) Celebrates FDA Milestone: First MSC Cell Therapy Approval Validates Regenerative Medicine Future - StockTitan
Adipose-derived Stem Cell Market Key Players Analysis - openPR
When the Price of (PLUR) Talks, People Listen - Stock Traders Daily
Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025 - The Manila Times
Pluri's PluriCDMO Nominated for CDMO of the Year Award, Showcasing Revolutionary Cell Therapy Manufacturing - StockTitan
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing - Yahoo Finance
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - Marketscreener.com
(PLUR) Technical Data - Stock Traders Daily
Pluri Inc (PLUR): Worth A Small Bite At $5.57 - Stocks Register
Pluri Inc. faces Nasdaq delisting over equity shortfall - Investing.com
Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns - The Manila Times
Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear - EIN News
Pluri Readies Mass Production of Radiation Treatment Amid Global Nuclear Concerns - StockTitan
Pluri First Quarter 2025 Earnings: US$1.08 loss per share (vs US$0.96 loss in 1Q 2024) - Yahoo Finance
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - StreetInsider.com
BrainStorm Cell Reports $2.7M Loss, Plans Phase 3b ALS Trial Despite Low Cash | BCLI Stock News - StockTitan
Pluri: Fiscal Q1 Earnings Snapshot - San Francisco Chronicle
Pluri (PLUR) to Present at Q4 Virtual Investor Summit: Biotech Showcase for Growth | PLUR Stock News - StockTitan
Pluri (PLUR) Announces Key Collaboration, Driving Stock Upward - Stocks Telegraph
BrainStorm Teams with Pluri for Key NurOwn ALS Trial Manufacturing Partnership | PLUR Stock News - StockTitan
BrainStorm Teams with Pluri for Key NurOwn ALS Trial Manufacturing Partnership - StockTitan
Pluri And Bar-Ilan University Partner To Advance MAIT Cell Therapy For Solid Tumors - Contract Pharma
Pluri Flat on Funding From Innovation Authority - Baystreet.ca
Pluri Collaborates with Bar-Ilan University to Advance - GlobeNewswire
Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority - StockTitan
Cell And Gene Therapy Contract Development And Manufacturing - openPR
Renaissance Technologies LLC Decreases Position in Pluri Inc. (NASDAQ:PLUR) - Defense World
(PLUR) Technical Pivots with Risk Controls - Stock Traders Daily
Plurilock (PLUR.V) lands $19 million deal, largest in their history - Equity.Guru
Pluri Inc. regains compliance with Nasdaq listing rules - Investing.com India
3.95%
2.39%
자본화:
|
볼륨(24시간):